carteolol
Trade name: cartrol
Approved
Dec 28, 1988
Carteolol is a nonselective beta-adrenoceptor blocking agent for ophthalmic use. It has been shown to be effective in lowering intraocular pressure and may be used in patients with chronic open-angle glaucoma and intraocular hypertension. It may be used alone or in combination with other intraocular pressure lowering medications. The following adverse reactions have been reported: transient eye irritation, burning, tearing, conjunctival hyperemia and edema. Carteolol may cause bradycardia and decreased blood pressure, headache, arrhythmia, syncope, heart block, cerebral vascular accident, cerebral ischemia, congestive heart failure, palpitation, nausea, depression. Carteolol should be used with caution in patients who are receiving a beta-adrenergic blocking agent orally, because of the potential for additive effects on systemic beta-blockade. — NCATS
Clinical trial activity
5 trials · 3 clinical orgs · 6 marketing orgs
Earliest trial started Oct 1, 2009 (NCT00972426)
Timeline
1980s
- Dec 28, 1988
Earliest FDA Approval
- Dec 28, 1988
AbbVie — NDA Secondary Org
1990s
- May 23, 1990
Novartis — NDA Secondary Org
2000s
- Jan 3, 2000
Sandoz — Marketing Organization
- Jan 3, 2000
Novartis — Marketing Organization
- Jan 20, 2000
Bausch & Lomb — Marketing Organization
- Feb 6, 2002
Apotex — Marketing Organization
Indications
Mechanism of action
- Adrenergic receptor betaANTAGONIST
Adrenergic receptor beta antagonist
Approval history
- approvedDec 28, 1988
Chemistry & pharmacology
SMILES
CC(C)(C)NCC(O)COc1cccc2c1CCC(=O)N2- Mol. weight
- 292.38 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral, Topical
- Availability
- Prescription Only
Oral
Yes
Parenteral
No
Topical
Yes
Sources
- ChEMBLCHEMBL839 ↗
- WikipediaCarteolol ↗
- NCATS8NF31401XG ↗
- ChEMBLCHEMBL1201002 ↗
Also known as
- abbott-43326
- abbott-43326
- cartelol
- carteolol
- carteolol
- carteolol
- carteolol
- carteolol
- carteolol
- carteolol
- carteolol
- carteolol
- carteolol
- carteolol hcl
- carteolol hcl
- carteolol hcl
- carteolol hydrochloride
- carteolol hydrochloride
- carteolol hydrochloride
- carteolol hydrochloride
- carteololum
- carteololum
- cartrol
- cartrol
- cartrol
- dl-carteolol
- ocupress
- ocupress
- opc-1085
- opc-1085
- opc-1085
- teoptic
- teoptic
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05583474 | Phase 3 | Sep 27, 2022 | Fudan University, Otsuka |
| NCT02105272 | Phase 3 | Apr 1, 2014 | Otsuka |
| NCT02105285 | Phase 3 | Apr 1, 2014 | Otsuka |
| NCT02108288 | Phase 1 | Apr 1, 2014 | Otsuka |
| NCT00972426 | Phase 4 | Oct 1, 2009 | Government of Taiwan, Otsuka |
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Otsuka | For profit | 5 | 5 | 3 | 2009 |
| Fudan University | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Government of Taiwan | Government | 1 | 0 | 1 | 2009 |